ALCLS — Cellectis SA Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for Cellectis SA, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	59.6	38.6	25.7	9.19	49.2
Cost of Revenue
Gross Profit	13.5	-27.5	-18.7	-30.5	3.42
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	102	142	115	106	109
Operating Profit	-42.3	-103	-89.7	-97.3	-59.6
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-53.6	-96.8	-98.6	-116	-36.8
Provision for Income Taxes
Net Income After Taxes	-53.6	-96.8	-98.7	-117	-36.8
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-81.1	-114	-106	-101	-36.8
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-81.1	-114	-106	-101	-36.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.875	-1.92	-1.99	-1.92	-0.406
Dividends per Share